Sarepta Therapeutics Inc. (NASDAQ:SRPT) was upgraded by equities research analysts at JMP Securities to an “outperform” rating in a report issued on Monday. The brokerage currently has a $60.00 price target on the stock, up from their prior price target of $10.00. JMP Securities’ price target would indicate a potential upside of 7.66% from the company’s current price.
SRPT has been the topic of a number of other research reports. Leerink Swann upgraded shares of Sarepta Therapeutics from an “underperform” rating to a “market perform” rating and boosted their price target for the company from $5.00 to $50.00 in a report on Monday. Piper Jaffray Cos. raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Monday. Janney Montgomery Scott reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a research report on Tuesday, June 7th. Cowen and Company reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a research report on Tuesday, June 7th. Finally, William Blair raised shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research report on Monday. Two analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $51.01.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 55.73 on Monday. The stock’s market cap is $2.67 billion. The company’s 50-day moving average is $28.17 and its 200 day moving average is $21.37. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $56.80.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter last year, the business posted ($0.87) EPS. Equities research analysts anticipate that Sarepta Therapeutics will post ($4.98) EPS for the current year.
In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the sale, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at $2,309,490. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.90% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock valued at $59,227,000 after buying an additional 161,790 shares in the last quarter. State Street Corp increased its stake in Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock valued at $58,976,000 after buying an additional 625,051 shares in the last quarter. BlackRock Fund Advisors increased its stake in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock valued at $20,865,000 after buying an additional 25,799 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new stake in Sarepta Therapeutics during the first quarter valued at approximately $13,506,000. 72.09% of the stock is owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.